Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 19, 2014, Pages 7006-7011

  Rivlin, Noa ^a   Katz, Shir ^b   Doody, Maayan ^a   Sheffer, Michal ^a   Horesh, Stav ^a   Molchadsky, Alina ^a   Koifman, Gabriela ^a   Shetzer, Yoav ^a   Goldfinger, Naomi ^a   Rotter, Varda ^a   Geiger, Tamar ^b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA KINASE; HEAT SHOCK COGNATE PROTEIN 70; MITOGEN ACTIVATED PROTEIN KINASE 3; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN P21; PROTEIN P53; TRANSCRIPTION FACTOR NANOG; UBIQUITIN PROTEIN LIGASE NEDD4;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL TRANSFORMATION; CONFORMATIONAL TRANSITION; DNA DAMAGE; EMBRYO; EMBRYONIC STEM CELL; GENE MUTATION; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; KARYOTYPE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEOMICS; RNA SEQUENCE; SOMATIC CELL;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; EMBRYONIC DEVELOPMENT; EMBRYONIC STEM CELLS; HOMEODOMAIN PROTEINS; HUMANS; LI-FRAUMENI SYNDROME; LOSS OF HETEROZYGOSITY; MICE; MICE, KNOCKOUT; PROTEIN CONFORMATION; PROTEOMICS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84900470310     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1320428111     Document Type: Article

References (28)

1. Levine AJ, Oren M (2009) The first 30 years of p53: Growing ever more complex. Nat Rev Cancer 9(10):749-758.
2. Brosh R, Rotter V (2009) When mutants gain new powers: News from the mutant p53 field. Nat Rev Cancer 9(10):701-713.
3. Cañadillas JM, et al. (2006) Solution structure of p53 core domain: Structural basis for its instability. Proc Natl Acad Sci USA 103(7):2109-2114.
4. Donehower LA, et al. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356(6366):215-221.
5. Lang GA, et al. (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119(6):861-872.
6. Olive KP, et al. (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119(6):847-860.
7. Sah VP, et al. (1995) A subset of p53-deficient embryos exhibit exencephaly. Nat Genet 10(2):175-180.
8. Lin T, et al. (2005) p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 7(2):165-171.
9. Sabapathy K, Klemm M, Jaenisch R, Wagner EF (1997) Regulation of ES cell differentiation by functional and conformational modulation of p53. EMBO J 16(20):6217-6229.
10. Cervantes RB, Stringer JR, Shao C, Tischfield JA, Stambrook PJ (2002) Embryonic stem cells and somatic cells differ in mutation frequency and type. Proc Natl Acad Sci USA 99(6):3586-3590.
11. Varley JM, et al. (1997) A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. Oncogene 14(7):865-871.
12. Vojtesek B, et al. (1995) Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene 10(2):389-393.
13. Yewdell JW, Gannon JV, Lane DP (1986) Monoclonal antibody analysis of p53 expression in normal and transformed cells. J Virol 59(2):444-452.
14. Wang PL, Sait F, Winter G (2001) The 'wildtype' conformation of p53: Epitope mapping using hybrid proteins. Oncogene 20(18):2318-2324.
15. Lee DF, et al. (2012) Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. Cell Stem Cell 11(2):179-194.
16. Valpuesta JM, Martín-Benito J, Gómez-Puertas P, Carrascosa JL, Willison KR (2002) Structure and function of a protein folding machine: The eukaryotic cytosolic chap-eronin CCT. FEBS Lett 529(1):11-16.
17. Trinidad AG, et al. (2013) Interaction of p53 with the CCT complex promotes protein folding and wild-type p53 activity. Mol Cell 50(6):805-17.
18. Satija YK, Bhardwaj A, Das S (2013) A portrayal of E3 ubiquitin ligases and deubi-quitylases in cancer. Int J Cancer 133(12):2759-2768.
19. Li M, et al. (2002) Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416(6881):648-653.
20. Allton K, et al. (2009) Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci USA 106(28):11612-11616.
21. Sarig R, et al. (2010) Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J Exp Med 207(10):2127-2140.
22. Bykov VJ, et al. (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8(3):282-288.
23. Wiman KG (2010) Pharmacological reactivation of mutant p53: From protein structure to the cancer patient. Oncogene 29(30):4245-4252.
24. Cheng J, Dutra A, Takesono A, Garrett-Beal L, Schwartzberg PL (2004) Improved generation of C57BL/6J mouse embryonic stem cells in a defined serum-free media. Genesis 39(2):100-104.
25. Goldstein I, et al. (2013) Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53. Carcinogenesis 34(1):190-198.
26. Trapnell C, Pachter L, Salzberg SL (2009) TopHat: Discovering splice junctions with RNA-Seq. Bioinformatics 25(9):1105-1111.
27. Hubner NC, et al. (2010) Quantitative proteomics combined with BACTransgeneOmics reveals in vivo protein interactions. J Cell Biol 189(4):739-754.
28. Wisniewski JR, Zougman A, Nagaraj N, Mann M (2009) Universal sample preparation method for proteome analysis. Nat Methods 6(5):359-362.